CD38在慢性B淋巴细胞白血病细胞上表达的临床意义  

Clinical Significance of CD38 Expression in Chronic B Lymphocytic Leukemia

作　　者：张文艺[1] 王冬侠[1] 曹军[1] 姜琪[1] 

机构地区：[1]中国中医血液专病治疗中心河北廊坊市中医院临床检验中心,河北廊坊065000

出　　处：《标记免疫分析与临床》2009年第3期136-139,共4页Labeled Immunoassays and Clinical Medicine

摘　　要：为探讨CD38在慢性B淋巴细胞白血病(B-CLL)细胞上表达的临床意义,用流式细胞仪检测了78例慢性B淋巴细胞白血病细胞上CD38的表达。结果显示,CD38的表达与患者年龄、骨髓中白血病细胞比例、外周血白细胞数目、血红蛋白含量、血小板数和脾肿大无关(P>0.05),而与Binet分期(C期)、外周血白血病细胞比例、淋巴结肿大和肝肿大有关(P值分别为0.017、0.037、0.039、0.038),并有明显缩短的生存期(P=0.032)。结论:CD38高表达是B-CLL患者预后差的一个可靠指标。To explore the clinical significance of CD38 expression in chronic B lymphocytic leukemia （B-CLL） the expression of CD38 in 78 cases with B-CLL expressions in chronic B ripheral blood, overall survival. lymphocytic leukemia were analyzed by flow cytometry. The results showed that CD38 were significantly related with Binet stage, B-CLL cells in pelymphadenopathy and hepatomegaly. The patients with CD38 over-expression showed a shorter The CD38 expression could be as a poor prognostic indicator in B-CLL.

关 键 词：慢性B淋巴细胞白血病 CD38 流式细胞仪 预后 

分 类 号：R733.7[医药卫生—肿瘤]